December 3, 2024
RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results
November 27, 2024
Happy Thanksgiving ... giving thanks and be SAFE!
November 7, 2024
RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates
October 3, 2024
RegMedInvestors (RMi) Research Note: Editas Medicine asset sale raises $57+ M non -dilutive financing
September 10, 2024
RegMed Investors (RMi) Research Note: Ionis Pharmaceuticals (IONS) prices a $500.3 M public offering
August 30, 2024
RegMed Investors (RMi) Research Note: Harvard Apparatus RT (OTCQB: HRGN) raises $5 M without name identification
August 19, 2024
RegMed Investors (RMI) Research Note: Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Reports Q2/24 results
July 15, 2024
RegMed Investors (RMi) Research note: LENZ Therapeutics (LENZ +$0.16 to $21.19 at open) $30 M PIPE financing
March 22, 2024
RegMed Investors (RMi) research note – Finance: Sangamo Therapeutics (SGMO) Proposes Offering of 24,761,905 shares priced at $0.84
March 18, 2024
RegMedInvestors (RMi) Research Note – finance: bluebird bio (BLUE)Secures up to $175 M Debt Financing with Hercules Capital
March 6, 2024
RegMed Investors (RMi) Research Note – Financing: Regenxbio (RGNX) prices 4.56 M share offering at $23.00
February 21, 2024
RegMed Investors (RMi) Research Note:CRISPR Therapeutics (CRSP) announces Registered Direct Offering (RDO) of $280 M priced at $71.50 per share
February 20, 2024
RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes
February 15, 2024
RegMed Investors (RMi) Research Note: Prime Medicine (PRME) Prices 19million share offering at $6.25
February 13, 2024
RegMed (RMI) Research Note: CRISPR Therapeutics (CRSP) Registered Direct Offering (RDO) $280 M offering priced at $71.50
February 5, 2024
RegMed Investors (RMi): Adverum Biotechnologies (ADVM) 106.25 M Share Private Placement priced at $1.20
January 18, 2024
RegMed Investors (RMi) Research Note: Mesoblast (MESO) FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L)
January 8, 2024
RegMed Investors (RMi) Research Note: Solid Biosciences (SLDB) Announces $109 Million Private Placement
January 5, 2024
RegMed Investors (RMi) Research Note: Voyager Therapeutics (VYGR) prices 7.77 M share public offering at $9.00 per share
January 2, 2024
RegMed Investors (RMi) Research Note: Voyager Therapeutics (VYGR) juices after Novartis (NVS) licensing deal
December 20, 2023
RegMed Investors (RMi): bluebird bio (BLUE) prices $1.50 for 83 m stock offering
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors